Rockville biotech RegenxBio launches clinical trial in muscular dystrophy

Rockville’s RegenxBio Inc., which is developing treatments for retinal and neurodegenerative diseases, has launched another clinical trial in a bid to get multiple products to market in the next few years. The clinical-stage biotech said Monday it has started a phase 1/2 trial of a gene therapy candidate for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness and atrophy. The study, now underway and recruiting patients, aims to evaluate the safety, tolerability and efficacy of the company’s one-time experimental treatment, called RGX-202.